<DOC>
	<DOCNO>NCT02376751</DOCNO>
	<brief_summary>This open-label , multicenter expand access protocol allow patient confirmed diagnosis Lysosomal Acid Lipase ( LAL ) Deficiency United States ( US ) , access sebelipase alfa ( recombinant lysosomal acid lipase [ rhLAL ] ) commercial product available . Patients enrol expanded access protocol receive 1 mg/kg intravenous infusion sebelipase alfa every week .</brief_summary>
	<brief_title>An Expanded Access Protocol Sebelipase Alfa Patients With Lysosomal Acid Lipase Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>1 . Patient â‰¥ 8 month age commencement treatment sebelipase alfa . 2 . Patient confirm diagnosis LAL Deficiency . 3 . Patient patient 's parent legal guardian ( applicable ) consent participation study . If patient minor age , he/she willing provide assent require per local regulation , deem able . 4 . Male female patient childbearing potential must use highly reliable method birth control ( expect failure rate le 5 % per year ) time commence treatment 4 week last dose sebelipase alfa . 5 . Women childbearing potential must negative serum pregnancy test commencement treatment sebelipase alfa . 1 . Women nurse pregnant . 2 . Patients receive investigational product within 30 day ( small molecule ) 60 day ( biologic ) commence treatment , opinion investigator Sponsor , may negatively impact patient safety . 3 . Patients receive sebelipase alfa part clinical trial currently active . 4 . Patients know hypersensitivity egg .</criteria>
	<gender>All</gender>
	<minimum_age>8 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cholesteryl Ester Storage Disease</keyword>
	<keyword>Acid lipase disease</keyword>
	<keyword>Cholesterol ester hydrolase deficiency</keyword>
	<keyword>LIPA Deficiency</keyword>
	<keyword>Wolman disease</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
</DOC>